HNGE president reports 15,000-share insider sale at ~$44–46

Q: Who is the reporting person in the HNGE Form 4 and what is their role?

The reporting person is an officer of Hinge Health, Inc., serving as President , as indicated in the relationship section of the form.

Q: At what prices were the Hinge Health (HNGE) shares sold in this insider trade?

The sales were reported at weighted average prices of $44.3538 , $45.7528 , and $46.0885 , within price ranges from $43.96 to $46.21 .

Q: Were the Hinge Health (HNGE) insider sales made under a Rule 10b5-1 trading plan?

Yes. The filing states the sales were effected under a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025 .

Q: How many separate transactions are detailed in this HNGE Form 4?

The Form 4 lists three separate sale transactions of Class A common stock on 11/21/2025 , each with its own share amount and weighted average price.

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Hinge Health, Inc. (HNGE) President insider sale reported. A company officer filed a Form 4 showing open-market sales of a total of 15,000 shares of Class A common stock on 11/21/2025, executed in three transactions.

The shares were sold at weighted average prices of $44.3538, $45.7528, and $46.0885, within disclosed price ranges from $43.96 to $46.21. The transactions were made under a Rule 10b5-1 trading plan adopted on June 12, 2025. Following these sales, the reporting person directly holds 789,902 shares of Class A common stock.

Insider Trade Summary

Net Seller: 15,000 shares ($683,487)

Net Sell 3 txns

Insider Pursley James

Role President

Sold 15,000 shs ($683K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	2,714	$44.3538	$120K
Sale	Class A Common Stock	9,332	$45.7528	$427K
Sale	Class A Common Stock	2,954	$46.0885	$136K

Holdings After Transaction: Class A Common Stock — 802,190 shares (Direct)

Footnotes (1)

The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025. Represents the weighted average sale price. The lowest price at which shares were sold was $43.96 and the highest price at which shares were sold was $44.94. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Represents the weighted average sale price. The lowest price at which shares were sold was $45.01 and the highest price at which shares were sold was $46.00. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Represents the weighted average sale price. The lowest price at which shares were sold was $46.01 and the highest price at which shares were sold was $46.21. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Form 4 Insider Transactions: What Each Field Means →

11/24/2025 - 04:28 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pursley James

(Last)

(First)

(Middle)

C/O HINGE HEALTH, INC.

455 MARKET STREET, SUITE 700

(Street)

SAN FRANCISCO

94105

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Hinge Health, Inc. [ HNGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President

3. Date of Earliest Transaction (Month/Day/Year)
11/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	11/21/2025		S⁽¹⁾		2,714	D	$44.3538⁽²⁾	802,190	D
Class A Common Stock	11/21/2025		S⁽¹⁾		9,332	D	$45.7528⁽³⁾	792,856	D
Class A Common Stock	11/21/2025		S⁽¹⁾		2,954	D	$46.0885⁽⁴⁾	789,902	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025.

2. Represents the weighted average sale price. The lowest price at which shares were sold was $43.96 and the highest price at which shares were sold was $44.94. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

3. Represents the weighted average sale price. The lowest price at which shares were sold was $45.01 and the highest price at which shares were sold was $46.00. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

4. Represents the weighted average sale price. The lowest price at which shares were sold was $46.01 and the highest price at which shares were sold was $46.21. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

	/s/ James Budge, Attorney-in-Fact	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Hinge Health (HNGE) report in this Form 4?

The Form 4 reports that a Hinge Health, Inc. officer sold a total of 15,000 shares of Class A common stock in open-market transactions on 11/21/2025.

Who is the reporting person in the HNGE Form 4 and what is their role?

The reporting person is an officer of Hinge Health, Inc., serving as President, as indicated in the relationship section of the form.

At what prices were the Hinge Health (HNGE) shares sold in this insider trade?

The sales were reported at weighted average prices of $44.3538, $45.7528, and $46.0885, within price ranges from $43.96 to $46.21.

How many Hinge Health (HNGE) shares does the insider own after the reported sales?

After the reported transactions, the officer beneficially owns 789,902 shares of Hinge Health Class A common stock, held directly.

Were the Hinge Health (HNGE) insider sales made under a Rule 10b5-1 trading plan?

Yes. The filing states the sales were effected under a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025.

How many separate transactions are detailed in this HNGE Form 4?

The Form 4 lists three separate sale transactions of Class A common stock on 11/21/2025, each with its own share amount and weighted average price.

Does the HNGE Form 4 specify that detailed price information is available on request?

Yes. For each weighted average sale price, the reporting person undertakes to provide full price-by-trade details to the SEC staff, the issuer, or stockholders upon request.